Background
==========

Several clinical studies have shown that plant stanol esters are effective cholesterol-lowering agents \[[@B1],[@B2]\]. The cholesterol-lowering effect of dietary plant stanol ester has been shown to be sustained for periods up to 12 months \[[@B1]\], but how soon full cholesterol-lowering effect of plant stanol esters can be obtained, is still unclear. In most previous studies \[[@B3]-[@B5]\] the vast proportion of reduction in serum cholesterol has been reported to occur within 2--3 weeks, but the effects of plant stanol esters probably appear sooner than that. The results from two clinical studies with normo- or hypercholesterolemic subjects, where the cholesterol measurements have also been done at time point of one week, are conflicting: In one study \[[@B6]\], maximal cholesterol-lowering effect was obtained within a week of dietary plant stanol ester use, whereas in the other \[[@B7]\], no effect on serum cholesterol concentrations was obtained after one week of dietary plant stanol ester use. On the other hand, in a specific patient group, in colectomized patients \[[@B8]\], significant reduction in serum cholesterol was found already after one day of stanol ester use as measured by gas liquid chromatograph (GLC), but a steady state was reached just within one week. However, as far as we know, short-term cholesterol-lowering effects of plant stanol esters have not been studied at several repeated time points within short period of time in a real target group for use of stanol ester-enriched products, i.e. hypercholesterolemic subjects. Therefore, in the present study our aim was to find out the time needed to obtain the full cholesterol-lowering effect of plant stanol esters with a daily dose of 2.0 g stanols in healthy, hypercholesterolemic subjects.

Methods
=======

Subjects
--------

Altogether 11 mildly to moderately hypercholesterolemic (10 men and 1 women) subjects were recruited to the study from subjects participated the former studies carried out at the Department of Clinical Nutrition, University of Kuopio. The main inclusion criteria were as follows: serum total cholesterol 5.0--8.5 mmol/l and total triglycerides below 2.5 mmol/l at screening. Other inclusion criteria were aged 25--65 years, normal liver, kidney and thyroid function, no lipid-lowering medication, no coronary heart disease, no diabetes mellitus, no gastrointestinal diseases, no alcohol abuse (\>45 g of ethanol/d) and no irregular eating habits. One subject used postmenopausal estrogen therapy, one used a betablocker for the treatment of hypertension and one used anti-thrombolytic medication. Two subjects were smokers. The subjects were requested to keep their medication, weight, alcohol consumption, smoking habits and physical activity constant during the study. All 11 subjects completed the study. Their mean age was 50.2 ± 8.8 y and mean body mass index (BMI) was 27.0 ± 2.8 kg/m^2^. Baseline (0 day) total, LDL, HDL and VLDL cholesterol and triglyceride concentrations are shown in Table [2](#T2){ref-type="table"}.

###### 

Serum lipids and lipoproteins (mmol/l) during the study.

                      **Experimental period**   **Follow-up period**                                                                         
  ------------------- ------------------------- ---------------------- ---------------- ---------------- ------------- ------------- ------- -------
  Total cholesterol   6.33 ± 0.64               6.16 ± 0.74            5.81 ± 0.76^a^   6.06 ± 0.83      6.16 ± 0.75   6.30 ± 0.87   0.014   0.316
  LDL cholesterol     4.51 ± 0.66               4.34 ± 0.69            4.06 ± 0.75^a^   4.04 ± 0.68^a^   4.21 ± 0.67   4.26 ± 0.72   0.001   0.183
  HDL cholesterol     1.36 ± 0.31               1.34 ± 0.31            1.31 ± 0.30      1.36 ± 0.30      1.35 ± 0.34   1.37 ± 0.35   0.247   0.935
  VLDL cholesterol    0.47 ± 0.26               0.48 ± 0.22            0.44 ± 0.27      0.67 ± 0.21^a^   0.60 ± 0.18   0.66 ± 0.54   0.011   0.811
  Triglycerides       1.61 ± 0.54               1.41 ± 0.55            1.40 ± 0.57      1.61 ± 0.59      1.47 ± 0.46   1.90 ± 1.04   0.311   0.236

Values are means ± SD, n = 11. ^1^ indicate the significance of the differences for overall changes during the experimental period (days 0--15) analyzed with analysis of variance for repeated measurements (MANOVA). ^2^ indicate the significance of the differences for overall changes during the follow-up period (days 15--22) analyzed with analysis of variance for repeated measurements (MANOVA). ^a^ p \< 0.05 significantly different from the values of 0 day analyzed with paired t-test with Bonferroni correction.

Footnotes. During the experimental period the percentage changes (versus 0 day) in serum total cholesterol were -2.6 ± 8.1%, -8.2 ± 8.7% and -4.3 ± 8.1% at days 4, 8 and 15, respectively, and during the follow up period the changes were -2.7 ± 7.2% and -0.6 ± 8.8% at days 17/18 and 22, respectively. Respective changes in serum LDL cholesterol were -3.5 ± 8.9%, -9.9 ± 10.4%, -10.2 ± 10.5%, -6.5 ± 8.7% and -5.3 ± 10.0%.

The subjects gave their informed consent for the study and study protocol was approved by the Ethics Committee of the Kuopio University Hospital.

Study design
------------

The study was carried out at the Department of Clinical Nutrition, University of Kuopio with the open and uncontrolled study design. The study lasted three weeks including six visits to the study unit. Subjects started the study in two batches so that one started a week later than the other batch. For 14 days the subjects consumed the test margarine daily and during this period the fasting blood samples were taken at the beginning of the experimental period (0 day) and at days 4, 8 and 15 (meaning 3, 7 and 14 days after the initiation of test margarine consumption, respectively). The returning of the serum lipid concentration was followed two times after 2 or 3 days (17 or 18 days) and after 7 days (22 days) from the end of the test spread consumption.

At the first visit of the study (0 day) routine laboratory measurements were taken to ensure normal health status. In addition, medical history, use of drugs and nutrient supplements, alcohol consumption, smoking habits and physical activity were interviewed using a structured questionnaire. The possible changes in dietary habits, health status and physical activity were asked to record in the follow-up diary during the trial. The possible adverse effects and symptoms were enquired based on a structured questionnaire at the end of the experimental period (15 days).

Diet
----

The subjects followed their habitual diet except replacing 25 g of their normal fat spread with rapeseed oil-based stanol ester margarine daily (Benecol-80^®^, Raisio Group Plc, Raisio, Finland). The fat content of test margarine was 72.5 %. Plant stanol esters were prepared from wood and vegetable sterols (DRT, Les Derives Resiniques & Terpeniques Granel S.A. Dax Cedex, France and Archer Daniels Midland Co, Decatur, IL, respectively) by recrystallization, hydrogenation to form plant stanols, and esterification with low-erucic acid rapeseed oil-based fatty acids to produce fatty acid esters of plant stanols. The margarine contained 8.0 weight-% total stanols including 6.1 weight-% sitostanol and 1.9 weight-% campestanol. Thus the targeted daily intake of total stanols based on the actual amount of stanols in test spread was 2.0 g (1.52 g sitostanol and 0.47 g campestanol).

The subjects received the tubs of test margarine when visiting the study unit. They were given detailed instructions on how to use the test spread. Furthermore, the subjects were asked to record the use of test spread daily and to return the empty and partly empty tubs and the extra tub of test spread to the study unit at the end of experimental period. The packages and the test spread left over were weighed and the result recorded.

The background diet of the subjects was monitored by seven-day food record (five weekdays and two weekend days) and nutrient intake was calculated from the records by using the Micro-Nutrica^®^ dietary analysis program (version 2.0, Finnish Social Insurance Institute, Turku, Finland). The subjects kept the food record after the third study visit.

Laboratory measurements
-----------------------

All measurements were done and venous blood samples were obtained after 12-h overnight fast by using standardized methods. Body weight was measured with a digital scale.

Lipoproteins were separated by ultrasentrifugation for 18 h at density 1.006 to remove very low density lipoprotein (VLDL). HDL in the infranatant was separated from LDL by precipitation of LDL with dextran sulfate and magnesium chloride \[[@B9]\]. LDL cholesterol was calculated as the difference between the mass of cholesterol in the infranatant and HDL, and VLDL cholesterol was calculated as difference between the whole serum and the infranatant. Enzymatic photometric methods were used for the determination of cholesterol and triglycerides from whole serum and separated lipoproteins using commercial kits (Monotest^®^ Cholesterol and Triglyceride GPO-PAP, Boehringer Mannheim GmbH Diagnostica, Mannheim, Germany) with a Kone Specific Clinical Analyser (Kone Ltd., Espoo, Finland). The coefficients of variation between measurements for serum total cholesterol were 1.4--1.7%, for triglycerides were 2.1--2.2%, for HDL cholesterol were 0.4--1.4% and for HDL triglycerides was 0.8%.

Serum cholesterol precursors, cholestanol and plant sterols were measured by GLC (HP 5890 Series II, Hewlett Packard, Delaware, Little Falls, USA) from nonsaponifiable serum material \[[@B10],[@B11]\] equipped with a 50-m long Ultra 1 capillary column (Methyl-polysiloxane) (Hewlett Packard, Delaware, Little Falls, USA) for cholestanol, desmosterol, squalene, 8Δ-cholestenol, 7Δ-lathosterol, campesterol and sitosterol, and equipped with a 50-m long Ultra 2 capillary column (5 % Phenyl-methyl siloxane) (Hewlett Packard, Delaware, Little Falls, USA) for sitostanol and campestanol. 5α-cholestanol for cholesterol and epi-coprostanol for cholesterol precursors, plant sterols and cholestanol were used as internal standards. Serum cholesterol precursors, cholestanol and plant sterols were determined twice and the mean value of two measurements was used in the statistical analysis. To eliminate the effects of the impact of changes in the amount of sterol transporting lipoprotein particles, values of above-mentioned variables are presented in terms of 10^-2^mg/mg of cholesterol (GLC), which express ratio to total cholesterol.

Plasma glucose was analyzed by enzymatic photometric method using reagent Granutest 100 (Merck, Damstadt, Germany) with a Kone Specific Clinical Analyser (Kone Ltd., Espoo, Finland).

Statistical analyses
--------------------

All statistical analyses were performed with SPSS for windows 6.0.1 statistics program (SPSS, Chicago, IL, USA) \[[@B12]\]. The results are given as means ± SDs and in some cases also as range. Normal distribution of variables was checked with Shapiro Wilks test before the further analyses. If a variable was not normally distributed statistical analysis was made after logarithmic transformation. Simple factorial analysis of variance (ANOVA) was used to test whether there were differences in the initial measurements of each period (0 day and 15 days) between two starting batches. Analysis of variance for repeated measurements (MANOVA) was used to compare the overall changes in continuous variables among different dose periods. Two-tailed comparisons with paired t-test were used in the further analyses. For variables which were not normally distributed not even after logarithmic transformation Friedman Two-tailed ANOVA test or Wilcoxon matched-paired signed rank test or Mann-Whitney test was used. To control the overall level Bonferroni adjustment was used.

Results
=======

Baseline Characteristics
------------------------

During the experimental period BMI decreased \<1%, from 27.0 ± 2.8 to 26.7 ± 2.7 kg/m^2^ (P \< 0.01), whereas during the follow-up period BMI remained unchanged. Because the change of BMI was significant during the experimental period, the analyses of that period were made both with and without BMI as covariate. Medication, physical activity and smoking habits remained stable. No side effects were found during the experimental period.

Feasibility of the diet
-----------------------

The intake of nutrients of background diet during the experimental period are presented in Table [1](#T1){ref-type="table"}. The mean daily consumption of margarine according to the weighed returned tubs was 25.4 ± 0.8 g (24.4--27.5 g). Thus the actual daily intake of stanol was 2.03 ± 0.06 g (1.54 ± 0.05 g sitostanol and 0.48 ± 0.02 g campestanol).

###### 

Daily intake of energy and nutrients during the study.

  Nutrients                                   Habitual diet
  ------------------------------------------- ---------------
  Energy (kcal)                               2112 ± 507
  Fat (% of energy)                           33.3 ± 3.4
  Saturated fatty acids (% of energy)         11.2 ± 1.5
  Monounsaturated fatty acids (% of energy)   13.0 ± 1.8
  Polyunsaturated fatty acids (% of energy)   6.4 ± 0.9
  Proteins (% of energy)                      15.7 ± 1.8
  Carbohydrates (% of energy)                 45.4 ± 5.6
  Alcohol (% of energy)                       4.3 ± 3.6
  Cholesterol (mg)                            219 ± 67
  Fiber (g)                                   24.5 ± 6.7
  Vitamin A (μg RE/day)^1^                    977 ± 550
  β-carotene (μg/day)                         2901 ± 2685
  Vitamin D (μg/day)                          5.6 ± 2.5
  Vitamin E (mg/day)                          12.3 ± 1.5

Values are means ± SD, n = 11 ^1^ RE = retinol equivalents

Serum lipids and lipoproteins
-----------------------------

Serum lipid and lipoprotein concentrations are presented in Table [2](#T2){ref-type="table"}.

No significant differences were found in the mean values of serum lipids and lipoproteins at 0 and 15 days between the two starting batches. Furthermore, though the first follow-up blood sample was taken from first batch the day before (17 day) than from the second batch (18 day), no significant differences were found in serum lipids and lipoprotein concentrations in the first follow-up sample between the two starting batches.

During the experimental period serum LDL cholesterol concentration decreased slightly already at 4 days, but the decrease was not significant until at 8 days (Table [2](#T2){ref-type="table"}). In addition, no further decrease in serum LDL cholesterol concentration was found from the 8 to 15 days. At the time points 8 and 15 days the decrease of serum LDL cholesterol was significant even when the changes in BMI were taken into account in the analysis as covariate (P = 0.012--0.051). The reductions in serum total cholesterol paralleled the reductions in serum LDL cholesterol except at 15 days due to the significant increase of VLDL cholesterol. There were no significant changes in serum HDL cholesterol and triglyceride concentrations during the experimental period (Table [2](#T2){ref-type="table"}).

During the follow-up period serum total and LDL cholesterol concentrations began to return immediately after termination of test spread consumption, but the changes were significant neither at 17/18 days nor at 22 days. At 22 days serum LDL cholesterol concentration was still 5.3 ± 10.0 % lower than the initial value (0 day).

Plant sterols and cholesterol precursors
----------------------------------------

The results of serum plant sterols, cholestanol and cholesterol precursors are shown in Table [3](#T3){ref-type="table"}. There were significant differences in the mean values of serum sitosterol at the 0 and 15 days between the two starting batches, therefore the initial values were taken into account in the analyses as a covariate.

###### 

Ratios of serum cholesterol precursors and plant sterols to total cholesterol (10^-2^mg/mg of cholesterol) during the study.

                      **Experimental period**   **Follow-up period**                                                                                   
  ------------------- ------------------------- ---------------------- ---------------- ---------------- ---------------- ---------------- ----------- -------------
  Squalene/TC         0.49 ± 0.12               0.46 ± 0.14            0.55 ± 0.20      0.51± 0.12       0.46 ± 0.14      0.48 ± 0.20      0.390       0.662
  Δ8-cholestenol/TC   0.22 ± 0.09               0.22 ± 0.09            0.24 ± 0.06      0.25 ± 0.08      0.24 ± 0.07      0.23 ± 0.07      0.101       0.280
  Δ7-lathosterol/TC   1.67 ± 0.58               1.75 ± 0.60            1.89 ± 0.34      1.98 ± 0.48^a^   1.86 ± 0.46      1.71 ± 0.45      0.012       0.116
  Desmosterol/TC      1.05 ± 0.26               1.01 ± 0.18            1.09 ± 0.15      1.13 ± 0.14      1.04 ± 0.15^b^   1.06 ± 0.13      0.026       0.018
  Campesterol/TC      2.86 ± 0.89               2.58 ± 0.81^c^         2.38 ± 0.69^a^   2.14 ± 0.58^c^   2.44 ± 0.59^d^   2.57 ± 0.65^e^   0.001       \<0.001
  Sitosterol/TC       1.42 ± 0.50               1.28 ± 0.45^a^         1.16 ± 0.38^c^   1.04 ± 0.34^c^   1.17 ± 0.36^d^   1.28 ± 0.39^d^   0.004^\*^   \<0.001^\*^
  Avenasterol/TC      0.49 ± 0.13               0.44 ± 0.12^f^         0.45 ± 0.11      0.42 ± 0.07^f^   0.44 ± 0.10      0.44 ± 0.12      0.013       0.336
  Campestanol/TC      0.02 ± 0.08               0.04 ± 0.02^f^         0.07 ± 0.03^c^   0.07 ± 0.02^c^   0.05 ± 0.02^b^   0.03 ± 0.09^d^   \<0.001     \<0.001
  Sitostanol/TC       0.08 ± 0.04               0.13 ± 0.07^a^         0.16 ± 0.05^c^   0.18 ± 0.04^c^   0.15 ± 0.04^e^   0.12 ± 0.04^d^   \<0.001     \<0.001
  Cholestanol/TC      1.32 ± 0.26               1.30 ± 0.27            1.39 ± 0.24      1.30 ± 0.23      1.32 ± 0.28      1.31 ± 0.28      0.185       0.517

Values are means ± SD, n = 11. TC = total cholesterol ^1^ indicates the significance of the differences for overall changes during the experimental period (days 0--15) ^2^ indicates the significance of the differences for overall changes during the follow-up period (days 15--22) analyzed with analysis of variance for repeated measurements (MANOVA) or Friedman Two-way ANOVA test (Avenasterol/TC). ^\*^ Initial concentration (0 day or 15 days) was significantly different by ANOVA between the two starting batches; therefore, the initial concentration was taken into account in the analyses as a covariate. ^a^ P \< 0.01, ^c^ P \< 0.001, ^f^ P \< 0.05 significantly different from the values of 0 day analyzed with paired t-test or Wilcoxon matched-paired test with Bonferroni correction. ^b^ P \< 0.05, ^d^ P \< 0.001, ^e^ P \< 0.01 significantly different from the values of 15 days analyzed with paired t-test with Bonferroni correction.

Serum plant sterols, and in particular serum campesterol/total cholesterol ratio, which reflects cholesterol absorption efficacy \[[@B13]-[@B15]\], reduced significantly already at 4 days (Table [3](#T3){ref-type="table"}). In contrast, the ratios of serum campestanol and sitostanol to total cholesterol increased significantly during the experimental period and the significant increase was reached in 4 days. However, after termination of test spread consumption serum campestanol and sitostanol decreased rapidly and the reduction was significant already at 17/18 days. At 22 days serum campestanol/total cholesterol ratio had almost returned to baseline (P = 0.614), but sitostanol/total cholesterol ratio was slightly, but still significantly, greater than baseline (P = 0.033).

Serum 7Δ-lathosterol/total cholesterol ratio, which reflects cholesterol synthesis \[[@B13],[@B14],[@B16]\], increased during the experimental period and the increase was statistically significant at 15 days compared with the initial value (Table [3](#T3){ref-type="table"}).

Discussion
==========

The main results of the present study with hypercholesterolemic subjects were that the significant decrease in serum LDL cholesterol concentrations was achieved already after one week of the initiation of stanol ester margarine consumption, and that no additional cholesterol-lowering effect was obtained between the 8th and 15th days (-9.9% and -10.2%, respectively). Our findings agree with the findings of Mensink et al. \[[@B6]\] in which full cholesterol-lowering effect was reached within one week with stanol ester use. These results are also in line with the values of two weeks of our dose-response study, where serum LDL cholesterol was reduced significantly by 10.5%, 11.2%, 17.4% and 17.4% versus control with the daily stanol dose of 0.8 g, 1.6 g, 2.4 g and 3.2 g, respectively \[[@B17]\]. In contrast to the above findings, Jones et al. \[[@B7]\] did not find any effect on serum cholesterol concentrations after one week with stanol ester use. It can be speculated that some background factors, such as changes in diet, might have confounded their results. In fact, the actual composition of the diet has not been reported in that study. Our study can be criticized because of the lack of the control group. It is clear that the fatty acid modification contributes to the serum cholesterol reduction, but this takes place after a few week consumption. Therefore, the changes in serum cholesterol concentrations in the present study can be ascribed to plant stanol ester use despite the lack of the control group. Furthermore, these results can be ascribed to plant stanol ester use, since the compliance of subjects was good according to the follow-up diaries and weighted returned tubs. In addition, the changes in serum plant sterol and stanol concentrations reveal the good compliance. Moreover, our results are supported by results from the studies of Mensink et al. \[[@B6]\] and Miettinen et al.\[[@B8]\].

In a specific patient group, in colectomized patients \[[@B8]\], significant reduction in serum cholesterol concentrations was reported already after one day of stanol ester consumption. However, in the present study with hypercholesterolemic subjects we found non-significant reduction in serum cholesterol at 4 days. The different results could be explained by different cholesterol metabolism between the healthy subjects and colectomized patients. In colectomized patients transit time is very short, on an average 4--6 hours, and removal of cholesterol is slightly increased \[[@B18],[@B19]\]. Our result in noncolectomized hypercholesterolemic subjects is not unexpected, since under normal circumstances the half-life of disappearance of LDL apo B-100 from the circulation is about 2½ days, therefore serum LDL cholesterol concentration can be expected to decrease significantly only after some days of stanol ester use \[[@B20]\].

Serum VLDL cholesterol concentration was significantly higher at 15 days compared with the initial value. However, this finding was likely occasional and due to temporary increased alcohol consumption -- about 2% higher than recorded in other studies -- since plant stanols have generally not been reported to affect serum VLDL cholesterol \[[@B21]-[@B26]\].

Hypocholesterolemic effect of plant stanol esters is based on their ability to inhibit cholesterol absorption effectively from small intestine \[[@B27]\]. Serum campesterol/total cholesterol ratio has been found to be an indirect marker of cholesterol absorption \[[@B13]-[@B15]\]. In the present study, serum campesterol/total cholesterol ratio decreased significantly already within 4 days indicating that intestinal cholesterol absorption reduces rapidly after the initiation of the stanol ester consumption. This support the finding that cholesterol-lowering effect of stanol esters appears very soon after the initiation of their consumption. On the other hand, during the experimental period serum 7Δ-lathosterol/cholesterol ratio \[[@B13],[@B14],[@B16]\] increased significantly reflecting the enhanced endogenous cholesterol synthesis as a feedback reaction to the reduced cholesterol absorption. Also in previous studies the synthesis of Δ7-lathosterol has been found to be stimulated by plant stanol esters \[[@B22],[@B23],[@B28]-[@B31]\]. In fact, Relas et al. \[[@B32]\] suggested that effectively increased endogenous cholesterol synthesis was a reason for the inconsistent decrease in serum total and LDL cholesterol after 2 weeks with stanol ester use in their study.

Similar to recent stanol ester studies \[[@B3],[@B8],[@B26],[@B31],[@B33]-[@B35]\], in the present study sitostanol and campestanol from stanol ester margarine seemed to be absorbed to some extent. However, the rapid reduction in serum plant stanol concentration after termination of the test margarine consumption, indicates that biliary elimination of plant stanols is rapid and that they are not stored in the human body.

During the follow-up period the returning of serum cholesterol to the initial values began rapidly after termination of the consumption of plant stanol esters. However, after one week serum LDL cholesterol value was still 5% lower than the initial value indicating that full return to the initial values after use of the plant stanol ester enriched-margarine does not take place within one week. This finding supports the finding of previous studies \[[@B1],[@B3],[@B6]\] in which the returning to baseline has been found to occur after two to three weeks of the termination. Therefore, consumption of products enriched with stanol esters should be regular in order to receive sustainable cholesterol-lowering effect. In addition to that it should be taken into account that although clinically significant benefit can be reached already within one week with the plant stanol ester use, a steady state in serum cholesterol concentrations is usually attained within 3--4 weeks. Therefore, serum cholesterol values are reasonable to follow at least that time, especially if there is need to match cholesterol-lowering drug therapy with the use of dietary plant stanol esters.

Conclusions
===========

In conclusion, effect of plant stanol esters on serum LDL cholesterol concentrations can fully be obtained within 1--2 weeks of the use of plant stanol ester-enriched margarine in hypercholesterolemic subjects.
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